Q2-Header_1280x350_8

Biomarker Testing Services

by Rules-Based Medicine, a Q² Solutions Company

The industry leader in multiplex immunoassay development and testing

Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA-certified biomarker testing laboratory developing immunoassays used to quantify protein biomarkers in support of drug mechanism of action, pharmacodynamic, prognostic, and predictive clinical studies across all stages of drug discovery and development. RBM is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (Simoa™) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.

What differentiates Rules-Based Medicine from its competitors is that they have spent over 20 years internally developing and manufacturing multiplex immunoassays validated to clinical laboratory standards for the Luminex xMAP® technology. Since 2014, they have applied these skills to building ultrasensitive immunoassays on the Simoa™ platform to quantify protein biomarkers previously difficult or impossible to measure. The RBM platform appropriately combines Luminex and Simoa™ microsphere-based immunoassays with the precision and dependability of automated liquid handling systems, advanced quality monitoring, validated data reporting processes, and a highly trained and dedicated staff including project managers. Together these features set RBM apart from other biomarker testing laboratories by providing the highest quality, cost-effective approach to measuring biomarkers from a variety of biological samples.

Why Choose Rules-Based Medicine for your Clinical Trial?

  • Long history of developing, validating, and manufacturing immunoassays allows us to provide customers with unmatched expertise in the field of protein biomarker testing.
  • Quality control measures in place for each and every step of the process, all in accordance with their strict standard operating procedures.
  • Four step quality control procedure including instruments diagnostics, calibrator curves at front and back end of each reaction plate, three levels of controls run in duplicate, and sample review.
  • TruCulture® – An integrated whole-blood collection and leukocyte culture system tube for immunophenotyping at clinical trial sites.

   

to learn more, visit:

Related Thought Leaders Insights


Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q2 Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-SEQ with BioLegend. Describes CITE-seq performance expectations for...

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

CNS Biomarkers

Rules-Based Medicine, a Q2 Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...